Therapy Directory

Rituximab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Rituximab as a study intervention. Browse Rituximab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1303

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Chronic Graft Versus Host Disease
Interventions: Belumosudil, Rituximab; Drug
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis
Interventions: Rituximab Infusion, Oral Cyclosporine; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Adult Burkitt Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, Epcoritamab, Etoposide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Rituximab, Vincristine; Procedure · Drug · Biological
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
Interventions: Rituximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Relapsed or Refractory Large B-cell Lymphoma
Interventions: Loncastuximab Tesirine, Rituximab; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Salt Lake City, Utah

Conditions: Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Interventions: TEDD-R, TEDDI-R, Ibrutinib, Cytarabine, Isavuconazole, Methotrexate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, NHL
Interventions: DA-EPOCH, Rituximab, CHOP, Acalabrutinib; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8
Interventions: Zidovudine, Liposomal Doxorubicin, Valganiclovir, Rituximab, Standard Therapies, Cohort 1; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Interventions: Iptacopan, Placebo, Rituximab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Mesa, Arizona • Rochester, Minnesota

Conditions: Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions: Rituximab, Tafasitamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Survey Administration; Biological · Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hairy Cell Leukemia
Interventions: Pentostatin, Rituximab, Bendamustine, Acetaminophen, Diphenhydramine, Epinephrine, Antihistamines, Corticosteroids, Bronchodilators, Intravenous (IV) Saline; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions: Nintedanib, Placebo, Standard of Care; Drug
Lead sponsor: Rohit Aggarwal, MD; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more

About this Rituximab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Rituximab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Rituximab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Rituximab clinical trials

Filter and sort this therapy

Live official records

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

Iptacopan in Patients With ANCA Associated Vasculitis

Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Myositis Interstitial Lung Disease Nintedanib Trial

About this Rituximab clinical trials directory page